GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Dividend Yield %

Alto Neuroscience (Alto Neuroscience) Dividend Yield % : 0.00% (As of May. 26, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Dividend Yield %?

As of today (2024-05-26), the Trailing Annual Dividend Yield of Alto Neuroscience is 0.00%.

The historical rank and industry rank for Alto Neuroscience's Dividend Yield % or its related term are showing as below:

ANRO's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.485
* Ranked among companies with meaningful Dividend Yield % only.

Alto Neuroscience's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.

As of today (2024-05-26), the Forward Dividend Yield % of Alto Neuroscience is 0.00%.

Alto Neuroscience's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Alto Neuroscience Dividend Yield % Historical Data

The historical data trend for Alto Neuroscience's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Dividend Yield % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Dividend Yield %
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Dividend Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Alto Neuroscience's Dividend Yield %

For the Biotechnology subindustry, Alto Neuroscience's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Dividend Yield % falls into.



Alto Neuroscience Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Alto Neuroscience  (NYSE:ANRO) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Alto Neuroscience Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus